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Abstract Background: The ﬁnding of an exudative effusion usually requires an extensive diagnos-
tic workup, leading to an unnecessary exposure to invasive and expensive diagnostic procedures.
Thus a strategy of identifying pleural effusions due to heart failure and possibly avoiding unneces-
sary diagnostic thoracentesis and/or further diagnostic procedures would be an attractive and
potentially beneﬁcial approach [6]. NT-proBNP measured in serum is a sensitive marker of cardiac
dysfunction and proven to be a useful tool in the diagnosis of acute and chronic systolic and dia-
stolic left ventricular heart failure [7,8].
Purpose: The present study was conducted to assess the diagnostic value of NT-proBNP in the
differentiation of cardiogenic and non cardiogenic pleural effusion.
Patients and methods: Forty patients with pleural effusion were included in this study. Twenty
patients with cardiogenic pleural effusions (pleural effusion due to cardiac cause) and 20 patients
with non cardiogenic pleural effusions (pleural effusion due to non cardiac cause). All patients were
subjected to full history, clinical examination, investigation to detect the etiology of the pleural effu-
sion and measurement of serum and pleural ﬂuid NT-proBNP.
Results: In this study we found that pleural ﬂuid NT-proBNP levels were signiﬁcantly higher in
patients with cardiogenic pleural effusions than that of patients with non cardiogenic pleural effu-
sions (Mean ± SEM, 5231 ± 671.1 and 628.8 ± 120.1 respectively, P value < 0.0001). Also NT-
proBNP levels in the serum of the patients with cardiogenic pleural effusions were signiﬁcantly
higher than that of patients with non cardiogenic pleural effusions (Mean ± SEM,
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4792 ± 612.7, and 604.0 ± 120.1 respectively, P value < 0.0001). There was also a highly signiﬁ-
cant positive correlation between NT-proBNP levels in serum and pleural ﬂuid Spearman’s Coefﬁ-
cient of rank correlation is 0.992 (p< 0.0001). We found also that at a cut-off value of 1.591 pg/ml,
pleural ﬂuid NT-proBNP level had a sensitivity of 95% and a speciﬁcity of 90% in the diagnosis of
cardiogenic pleural effusion. Also at a cut off value of 1570 pg/ml, serum NT-proBNP level had a
sensitivity of 95% and a speciﬁcity of 90% in the diagnosis of cardiogenic pleural effusion.
Conclusion: It is concluded that serum and pleural ﬂuid NT-proBNP levels are very useful in
establishing the diagnosis of cardiogenic pleural effusions.
ª 2012 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
Arabia. The study protocol was approved by the local ethics
committee. Informed consent was obtained from the patients.
The patients were classiﬁed according to their diagnosis
into 20 patients with cardiogenic effusion and 20 patients with
non-cardiogenic pleural effusion; 5 patients with malignant
pleural effusion, 5 patients with tuberculous pleural effusion,
5 patients with parapneumonic pleural effusion and 5 patients
with hepatic hydrothorax.
The diagnosis of cardiogenic pleural effusion was based on
ﬁndings of the typical clinical picture of decompensated heart
failure, including history, physical examination, chest radiogra-
phy, electrocardiography and response to diuretic therapy, and
conﬁrmed by echocardiographical evidence of left ventricular
systolic dysfunction and according to AHA guidelines [11].
Malignant effusions were diagnosed when malignant cells
were detected on cytological examination of pleural ﬂuid or
on pathological examination of pleural biopsy or lung biopsy
specimens in the absence of other causes of pleural effusion.
Tuberculous effusions were diagnosed when AFB were de-
tected in pleural ﬂuid or granuloma in pleural biopsy or lym-
phocytic pleural effusion with high ADA levels more than
40 u/l with positive tuberculine test, high ESR,and respond
to antituberculous treatment.
Parapneumonic effusions were diagnosed when the clinical
and radiological ﬁndings were compatible with pneumonia and
response to antimicrobial treatment and/or detection of pus or
positive bacterial cultures in pleural ﬂuid.
Hepatic hydrothorax was diagnosed when the pleural effu-
sion due to liver cirrhosis and there is ascites conﬁrmed by
abdominal ultrasound.
Inclusion criteria were any patient with radiologically deter-
mined pleural effusion that could be drained by thoracentesis
and the diagnosis was conﬁrmed. Exclusion criteria were any
patient with renal failure, coagulopathy, or thorax deformity
interfering with thoracentesis, or any effusion of undetermined
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CHF is probably the most common cause of pleural effusion
[1]. The incidence of pleural effusion in patients with CHF is
high. In one series of 60 patients with an exacerbation of stable
CHF, chest CT scans demonstrated that 50 patients (83%) had
a right-sided pleural effusion and 46 patients had a left-sided
effusion. Approximately one third of the effusions had a vol-
ume that exceeded 700 ml [2]. The pleural ﬂuid from a patient
with CHF is usually a transudate, as deﬁned previously by
Light’s criteria [3]. The criteria of Light et al. have been used
to make this differentiation. The main problem with those cri-
teria is that although they identify nearly all exudates correctly,
they misidentify about 20 to 25% of transudates as exudates
[4], especially after having received diuretic therapy [5].
The ﬁnding of an exudative effusion usually requires an
extensive diagnostic workup, leading to an unnecessary expo-
sure to invasive and expensive diagnostic procedures. Thus a
strategy of identifying pleural effusions due to heart failure
and possibly avoiding unnecessary diagnostic thoracenteses
and/or further diagnostic procedures would be an attractive
and potentially beneﬁcial approach [6].
B-type natriuretic peptide (BNP) is a vasoactive peptide pre-
dominantly secreted by the heart. Its precursor molecule, pro-
BNP, is cleaved to give the inactive N-terminal-pro-BNP (NT-
proBNP) and the biologically active BNP. The synthesis of these
peptides is stimulated by increased tension or stretching of the
cardiac ventricle wall. NT-proBNPmeasured in serum is a sensi-
tivemarker of cardiac dysfunction and proven to be a useful tool
in the diagnosis of acute and chronic systolic and diastolic left
ventricular heart failure [7,8]. Recently, the diagnostic value of
the NT-proBNP concentrations in pleural ﬂuid has been evalu-
ated and increased levels ofNT-proBNP in the pleural ﬂuid have
been showntobevaluable in thediscriminativediagnosisofpleu-
ral effusions related with cardiac disorders [9,10].Aim of the work
The aim of the present work was to investigate the diagnostic
value of measuring NT-proBNP levels in pleural ﬂuid and ser-
um of patients with cardiogenic and non cardiogenic pleural
effusions.
Patients and methods
Fourty patients with pleural effusions were prospectively stud-
ied between December, 2007 and November 2009 admitted at
Alhayah National Hospital, Khames Mushyt, Kingdom Saudi
origin, or with more than one possible cause.
All patients were subjected to the following: thorough med-
ical history and clinical examination. Radiological examina-
tion PA, Lateral, sometimes lateral decubitus views, chest
ultrasound and CT chest in selected patients. ECG and echo-
cardiography were done for All patients. CBC, ESR, renal
function, liver function and thoracentesis were done for all pa-
tients and pleural ﬂuid samples were sent for biochemical anal-
ysis, bacterial and fungal cultures, acid fast bacilli smear and
cytological examinations were performed to all patients
regardless to their clinical examination. Pleural biopsies were
sent for pathological examination in selected patients. Blood
and pleural ﬂuid specimens were collected in vacuumed tubes
then centrifuged 15 min at 3500 rpm serum and the superna-
tants were then removed and frozen at 70 c to be analyzed la-
ter for NT pro – BNP.
Levels of NT proBNP were measured using the fragment
EIA kit (Biomedica: Vienna, Austria) with detectable levels
of NT-proBNP ranging from zero to 1,000 fmol/ml. Using
the manufacturer-provided molecular weight, the upper limit
of this range was converted to 2,400 pg/ml (1 fmol = 2.4 pg).
Prior investigations using the same EIA kit reported their re-
sults in a similar manner [12,13].
Statistical analysis
Statistical Analysis was performed using MedCalc Software
Version 12.2.1 (MedCalc Software bvba .MedCalc Software,
Broekstraat 52, 9030 Mariakerke, Belgium). To compare two
independent samples we used an unpaired t-test. A p-value
of 0.05 was considered signiﬁcant. A correlation analysis be-
tween pleural ﬂuid and serum NT-proBNP concentration
was tested using Spearman’s correlation. Sensitivity, speciﬁcity
and accuracy were calculated according to standard formulae.
Exact binomial 95% conﬁdence intervals (CI) were calculated
for all operational characteristics. Receiver operating charac-
teristic (ROC) curve analysis was used to determine the dis-
criminative properties of various cut-off levels of NT-proBNP.
Results
In this study we found that pleural ﬂuid NT-proBNP levels
were signiﬁcantly higher in patients with cardiogenic pleural
effusions than that of patients with non cardiogenic pleural
effusions (Mean ± SEM, 5231 ± 671.1 and 628.8 ± 120.1
respectively, P value < 0.0001), (Tables 1 and 2) (see Tables
3 and 4).
There was also a highly signiﬁcant positive correlation be-
tween NT-proBNP levels in serum and pleural ﬂuid Spear-
man’s Coefﬁcient of rank correlation is 0.992 (p< 0.0001),
(Fig. 1)
We found also that at a cut-off value of 1.591 pg/ml, pleural
ﬂuid NT-proBNP level had a sensitivity of 95% and a speciﬁc-
ity of 90% in the diagnosis of cardiogenic pleural effusion,
(Fig. 2).
Criterion values and coordinates of the ROC curve.
Also at a cut off value of 1570 pg/ml, serum NT-proBNP
level had a sensitivity of 95% and a speciﬁcity of 90% in the
diagnosis of cardiogenic pleural effusion, (Fig. 3).
Criterion values and coordinates of the ROC curve.
Discussion
CHF is probably the most common cause of pleural effusion.
The incidence of pleural effusion in patients with CHF is high
[1]. The criteria of Light et al. have been used to make this dif-
ferentiation for the past 25 years. The main problem with those
criteria is that although they identify nearly all exudates cor-
rectly, they misidentify about 20–25% of transudates as exu-
dates [4]. Almost all of the patients with misclassiﬁed
transudates have heart failure and are receiving therapy with
diuretics. The serum NT-proBNP level is an established mar-
ker for the assessment of cardiac function, and has successfully
been used as a tool for the diagnosis and management of acute
and chronic heart failure, including systolic and diastolic left
ventricular dysfunction and valvular disease [7,8] .Pleural ﬂuid
NT-proBNP has been suggested to derive from serum NT-
proBNP which can diffuse into the pleural space [14]. Many
studies have demonstrated high serum and pleural ﬂuid NT-
proBNP concentrations in patients presenting with pleural
effusions due to decompensated heart failure [15,6,16].
In our study we found that pleural ﬂuid NT-proBNP levels
were signiﬁcantly higher in patients with cardiogenic pleural
effusions than that of patients with non cardiogenic pleural
effusions (Mean ± SEM, 5231 ± 671.1 and 628.8 ± 120.1
respectively, P value < 0.0001). Also NT-proBNP levels in
the serum of the patients with cardiogenic pleural effusions
were signiﬁcantly higher than that of patients with non cardio-
genic pleural effusions (Mean ± SEM, 4792 ± 612.7, and
604.0 ± 120.1 respectively, P value < 0.0001).
This ﬁnding is corresponding to the study done by Your-
gancioglu,et al. [17] who found that Median (25–75th percen-
tiles) NT-proBNP levels of serum and pleural ﬂuid due to
Table 1 Statistical comparison between cardiogenic group
and non cardiogenic group regarding to pleural ﬂuid levels of
NT proBNP (ng/ml).
Group Cardiogenic Non cardiogenic
No. 20 20
Range 1087–10460 153.0–1642
Mean ± SEM 5231 ± 671.1 628.8 ± 120.1
P value P< 0.0001 HS
HS =Highly Signiﬁcant.
Criterion Sensitivity 95% CI Speciﬁcity 95% CI +LR 95% CI LR 95% CI
>=146 100.00 83.2–100.0 0.00 0.0–16.8 1.00
>943 100.00 83.2–100.0 80.00 56.3–94.3 5.00 4.0–6.2 0.00
>1089 95.00 75.1–99.9 80.00 56.3–94.3 4.75 3.7–6.0 0.063 0.008–0.5
>1570* 95.00 75.1–99.9 90.00 68.3–98.8 9.50 8.0–11.3 0.056 0.005–0.6
>1590 85.00 62.1–96.8 90.00 68.3–98.8 8.50 6.7–10.8 0.17 0.03–0.9
Criterion Sensitivity 95% CI Speciﬁcity 95% CI +LR 95% CI LR 95% CI
>=153 100.00 83.2–100.0 0.00 0.0–16.8 1.00
>992 100.00 83.2–100.0 80.00 56.3–94.3 5.00 4.0–6.2 0.00
>1087 95.00 75.1–99.9 80.00 56.3–94.3 4.75 3.7–6.0 0.063 0.008–0.5
>1591* 95.00 75.1–99.9 90.00 68.3–98.8 9.50 8.0–11.3 0.056 0.005–0.6
>1594 90.00 68.3–98.8 90.00 68.3–98.8 9.00 7.3–11.1 0.11 0.02–0.7
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congestive heart failure (CHF) were 4747 pg/ml (931-15754)
and 4827 pg/ml (1290-12.430) while median NT-proBNP levels
of serum and pleural ﬂuid related with non-cardiac reasons
were 183 pg/ml (138-444) and 245 pg/ml (187-556) respectively.
NT-proBNP levels of serum and pleural ﬂuid were signiﬁcantly
high in CHF (p< 0.001 for both). The increased levels of NT-
proBNP in pleural ﬂuid and serum of patients with cardiogenic
pleural effusions compared to non cardiogenic pleural effu-
sions was consistently found in a number of studies done by
Seyhan et al. [18], Porcel et al. [16] and Kolditz et al. [6] who
demonstrated elevated levels of NT-proBNP in both serum
and pleural ﬂuid of individuals with pleural effusions arising
from cardiac disease. Additional investigations have conﬁrmed
the accuracy of NT-proBNP in identifying CHF-related pleu-
ral effusions, Han et al. [19] and Long et al. [13] who concluded
that NT-proBNP appears to be useful in differentiating be-
tween pleural effusions of cardiac and non cardiac origin.
In the present study Fig. 1 shows the correlation coefﬁcient
between serum and pleural ﬂuid NT-proBNP concentrations.
There was a highly signiﬁcant positive correlation between
NT- proBNP levels in serum and pleural ﬂuid,Spearman’s
Coefﬁcient of rank correlation is 0.992 (p< 0.0001). This con-
ﬁrms the data of Kolditz et al. [6] who found a close correla-
tion between NT-proBNP levels in pleural ﬂuid and serum,
leading to equal diagnostic efﬁcacy in the identiﬁcation of car-
diac effusions. Yorgancioglu et al. [17], found that serum and
pleural ﬂuid NT-proBNP concentration were signiﬁcantly re-
lated also – Tomcsanyi et al. [10], found a comparably high
correlation. The origin of NT-proBNP in pleural ﬂuid is un-
clear, but Zemans et al. [14] have been suggested that it derives
from serum NT-proBNP, and might diffuse easily into the
pleural space due to its small molecular size and this is could
be supported by the previously mentioned results. Therefore,
in case of risky diagnostic thoracentesis, plasma NT-proBNP
Table 2 Statistical comparisons between Pleural ﬂuid levels of NT proBNP (ng/ml) among the different studied groups.
Group CHF Malignant Parapneumonic TB Hepatic
No. 20 5 5 5 5
Range 1087–10460 298.0–1642 284.0–1596 153.0–1591 259.0–992.0
Mean ± SEM 5231 ± 671.10 833.2 ± 313.8 753.4 ± 224.9 483.4 ± 279.1 445.0 ± 137.7
P value 0.0061 HS 0.0017 HS 0.0039 HS 0.0002 HS
0.2671 NS 0.4129 NS 0.0698 NS
0.3427 NS 0.1827 NS
0.1000 NS
HS =Highly Signiﬁcant NS = Non Signiﬁcant.
Also NT-proBNP levels in the serum of the patients with cardiogenic pleural effusions were signiﬁcantly higher than that of patients with non
cardiogenic pleural effusions (Mean ± SEM, 4792 ± 612.7, and 604.0 ± 120.1 respectively, P value < 0.0001), (Tables 3 and 4).
Table 3 Statistical comparison between cardiogenic group
and non cardiogenic group regarding to Serum levels of NT
proBNP (ng/ml).
Group Cardiogenic Non cardiogenic
No. 20 20
Range 1089–9370 146.0–1594
Mean ± SEM 4792 ± 612.7 604.0 ± 120.1
P< 0.0001 HS
HS =Highly Signiﬁcant.
Table 4 Statistical comparisons between Serum levels of NT proBNP (ng/ml) among the different studied groups.
Group CHF Malignant Parapneumonic TB Hepatic
N 20 5 5 5 5
Range 1089–9370 267.0–1570 230.0–1594 146.0–1593 221.0–943.0
Mean ± SEM 4792 ± 612.7 800.0 ± 311.0 725.0 ± 232.6 473.8 ± 281.6 417.0 ± 132.8
0.0083 HS 0.0027 HS 0.0057 HS 0.0003 HS
0.2938 NS 0.4261 NS 0.0641 NS
0.3600 NS 0.1517 NS
0.0873 NS
HS =Highly Signiﬁcant NS = Non Signiﬁcant.






















Figure 1 Statistical correlation of serum & Pleural ﬂuid levels of
NT-proBNP. Spearman’s Coefﬁcient of rank correlation is 0.992
(p< 0.0001).
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measurements could be used as a predictor of cardiac origi-
nated pleural effusions Yourgancyoglu et al. [17].
In our study we found that at a cut-off value of 1,591 pg/
ml, pleural ﬂuid NT-proBNP level had a sensitivity of 95%
and a speciﬁcity of 90% in the diagnosis of heart failure with
pleural effusion. Also we found that at a cut off value of
1570 pg/ml, serum NT-proBNP level had a sensitivity of
95% and speciﬁcity 90% in the diagnosis of cardiogenic pleu-
ral effusion. Chang et al. [19] found the pleural ﬂuid NT-proB-
NP concentration of 1,714 pg/ml have a good accuracy for
detecting pleural effusion with heart failure (sensitivity 99%
and a speciﬁcity 99%). The pleural ﬂuid NT-proBNP cut-off
values for discriminating pleural effusion with heart failure
are variable from 1,176 pg/ml to 4,000 pg/ml [9,10].
Conclusion
In conclusion, measurement of serum and pleural ﬂuid NT-
proBNP levels showed high diagnostic accuracy in identifying
cardiogenic pleural effusion. They can be used to differentiate
pleural effusion due to cardiac cause from other causes of pleu-
ral effusions. Measuring NT-proBNP in serum can be used
alone as a diagnostic tool for the suggestion of cardiogenic
pleural effusions but further studies on large scales is
recommended.
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Figure 2 Receiver operating characteristic (ROC) curve of N-
terminal-pro-B-type natriuretic peptide (NT-proBNP) levels in
pleural effusion for differentiating between Cardiogenic and non
cardiogenic causes of pleural effusion. The AUC (area under
curve) for pleural ﬂuid NT-proBNP was 0.980 (95% conﬁdence
interval 0.876–1.000).
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Figure 3 ROC Curve of NT proBNP levels in Serum for
differentiation between Cardiogenic and non cardiogenic causes of
pleural effusion. The AUC for Serum NT-ProBNP was 0.980
(95% conﬁdence interval 0. 876–1.000).
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